According to the who data, lung cancer (lc) is the most common cancer (nearly 13,0 %) and prostate cancer (pc) is the second most common cancer (11,0 %) in men worldwide. In the chelyabinsk region, pc has been the most common cancer since 2019, accounting for 18,3 % of all cancer cases in males, and lc has become the second most common cancer, accounting for 6,8 %.The purpose of the study was to evaluate the epidemiological situation in terms of the most common cancers (lc and pc) in a male population of rural municipal areas in the constituent entity of the Russian Federation.Material and methods. The incidence and mortality of lung and prostate cancers were analyzed in 1020 males from five rural municipal districts of the chelyabinsk Region, territorially included in the magnitogorsk oncological cluster. Data were obtained from the population cancer Registry of the chelyabinsk Region for 2010–2019.Results. Over a ten-year period, the average detection rates for lc and pc were 103.59 ± 3.28 and 50.75 ± 4.86, respectively per 100,000 men in rural municipal areas. The average 1-year mortality rates from lc and pc were 59.33 ± 2.14 % and 21.11 ± 2.89 %, respectively. The average overall lc mortality was 85.44 ± 5.1 deaths per 100,000 men and the average overall pc mortality was 23.04 ± 1.26 deaths per 100,000.Discussion. The rates of the 1-year mortality from lc and pc, as well as the rates of the overall mortality from lc in men of rural municipal areas were higher than those in urban areas, demonstrating the tendency to increase.Conclusion. To ensure access to oncology medicine for patients in rural areas, private medical oncology clinics are involved on the basis of public-private partnership.
Introduction. The leading localizations of malignant neoplasms in terms of detection frequency in Russia are breast cancer (BC) and uterine cancer by women (RTM) — 51.8 and 18.3%, accordingly, by men — lung cancer (RL) and prostate cancer (PC) — 47.4 and 41.4%, respectively. Study objective was the identification of the main reasons of the high level of neglect of cancer of the leading localizations among residents of rural municipalities of the Chelyabinsk region. Material and methods. The study was carried out on the general population of people living in 5 rural municipal districts of the Chelyabinsk region, included by the Ministry of Health of the region in the Magnitogorsk oncological cluster, with malignant neoplasms of the mammary gland and the body of the uterus, lung and prostate gland (total 1696 observation units). Results. During medical examinations in basic rural municipal areas, the detection of breast cancer and RTM is in the range from 0.1 to 0.3 cases and 0.04 to 0.1 cases per 100 examined women, prostate cancer — 0.04-0.1 per 100 examined men. In medical examination suits, the detection is even lower — from 0.005 to 0.03 cases and 0.007 to 0.02 cases per 100 women and 0.01 to 0.05 cases per 100 men. The levels of cancer detection in rural areas are substantially lower than similar indicators among the urban population. Only when RL is detected, medical examinations of the rural population do not lag behind the indicators of the townspeople in their effectiveness. Discussion. The oncological epidemiological situation in municipal areas of the Magnitogorsk oncological cluster can be characterized as extremely unsatisfactory, due to a lower level of registered morbidity than in the city and to the low efficiency of active methods for detecting cancer. Conclusion. The lower incidence of malignant neoplasms in rural areas compared to urban indicators is due to the low efficiency of active methods for detecting neoplasms. The main way to identify malignant neoplasms of the leading localizations, with the exception of individual years of follow-up, is the independent appeal of rural patients to an oncologist, which causes a high level of neglect.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.